Cambridge Epigenetix Launches Innovative TrueMethyl Kits
Cambridge Epigenetix Ltd., a spin out biosciences company, has announced the launch of its TrueMethyl kits. Available to order now via its website at www.cambridge-epigenetix.com, the kits represent a ground-breaking development for the epigenetics industry.
TrueMethyl brings unprecedented clarity to the analysis of DNA by providing quantitative, accurate and repeatable single-base resolution sequencing of the modified bases hydroxymethylcytosine (5-hmC) and methylcytosine (5-mC) for the first time. Early studies indicate that these modifications may have distinct and important physiological functions.
Traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC. Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. The high quality and easy to use TrueMethyl kits utilise innovative oxidative bisulfite sequencing (oxBS-Seq), a chemistry-based technology invented by Prof. Shankar Balasubramanian and Michael Booth from the University of Cambridge.
TrueMethyl kits can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Trials of the kits conducted at leading research centers around the world have already begun to yield new insights into genome function and highlighted the advantages of TrueMethyl relative to traditional approaches.
Prof. Wolf Reik, group leader at the The Babraham Institute and the senior author of the recently published Cell Stem Cell paper which is the first published study using TrueMethyl said: “Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality. Consequently, this pioneering analytical method opens new avenues for basic research, pharmaceutical discovery and diagnostics. This technology was pivotal in enabling us to accurately profile 5-hmC and 5-mC during demethylation of DNA.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...